TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29072432
Drug: 7-day moxifloxacin-dexlansoprazole
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7-day moxifloxacin-dexlansoprazole based triple therapy with probiotic
Study: 29072432
Drug: 14-day moxifloxacin-dexlansoprazole
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14-day moxifloxacin-dexlansoprazole based triple therapy with probiotic
Study: 29072432
Drug: 7-day moxifloxacin-dexlansoprazole
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7-day moxifloxacin-dexlansoprazole based triple therapy with placebo
Study: 29072432
Drug: 14-day moxifloxacin-dexlansoprazole
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14-day moxifloxacin-dexlansoprazole based triple therapy with placebo
Study: 22136848
Drug: TSH suppressive
Normalized name: TSH-releasing hormone
DrugBank: Protirelin (DB09421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TSH suppressive therapy (group A)
Study: 22136848
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (group B)
Study: 16443858
Drug: nateglinide 30
Normalized name: nateglinide 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nateglinide 30 mg
Study: 16443858
Drug: glibenclamide 1.25
Normalized name: glibenclamide 1.25 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: glibenclamide 1.25 mg
Study: 11029017
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg with each meal, three times per day for 2.5 days)
Study: 9071623
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg single dose of ketoconazole (Regimen A)
Study: 9071623
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg daily dose of ketoconazole for 10 days (Regimen B)
Study: 7871052
Drug: Arecoline (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arecoline (low dose intravenous infusion for up to 2 weeks)
Study: 7871052
Drug: Arecoline (blinded,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arecoline (blinded, placebo-controlled, individualized optimal dosing for 5 days)
Study: 3518547
Drug: Naftidrofuryl (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl (3 X 200 mg tablets daily with meals)
Study: 3518547
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 tablets daily)
Study: 30206267
Drug: 2-g oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-g oral TXA 2 hours preoperatively
Study: 30206267
Drug: 20-mg/kg IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mg/kg IV TXA 5 minutes prior to incision
Study: 30206267
Drug: 2-g IA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-g IA TXA
Study: 25666427
Drug: High-dose CDDP
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose CDDP (810 mg)
Study: 25666427
Drug: Mid-dose CDDP
Normalized name: CDDP
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mid-dose CDDP (540 mg)
Study: 23434737
Drug: gD2-AS04 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gD2-AS04 vaccine formulations (20, 40, or 80 μg of truncated glycoprotein D from HSV-2 strain)
Study: 23434737
Drug: gD2-AS04 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gD2-AS04 vaccine formulations (different aluminum salts: AlPO₄ or Al(OH)₃)
Study: 23434737
Drug: gD2-AS04 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gD2-AS04 vaccine formulations (different preservatives)
Study: 23434737
Drug: gD2-AS04 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gD2-AS04 vaccine formulations (different volumes: 0.5 or 1 ml)
Study: 23434737
Drug: gD2-AS04 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gD2-AS04 vaccine formulations
Study: 20350333
Drug: Bosentan 500
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan 500 mg twice daily
Study: 16624552
Drug: High-dose imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose imatinib (800 mg daily)
Study: 16624552
Drug: Imatinib (general
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (general treatment)
Study: 1532316
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg slow release oral isradipine
Study: 2944997
Drug: Etodolac 200
Normalized name: etodolac 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac 200 mg
Study: 6212554
Drug: Etodolac 100
Normalized name: etodolac 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac 100 mg
Study: 29259382
Drug: Tolvaptan (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan (7.5 mg)
Study: 20552330
Drug: Lycopene capsules
Normalized name: lycopene Oral Capsule
DrugBank: Lycopene (DB11231)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lycopene capsules
Study: 20552330
Drug: Lycopene supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene supplementation (combined juice and capsules)
Study: 19567023
Drug: Chai Shao
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chai Shao Liu Jun Tang in combination with Lamivudine
Study: 17878255
Drug: Leptin levels
Normalized name: leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptin levels in women (12.5 ng/ml)
Study: 17878255
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein (CRP) levels in women (0.75 mg/liter)
Study: 17878255
Drug: Mendelian randomization
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mendelian randomization test for CRP as a causal agent for leptin
Study: 12402413
Drug: Maternal antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal antibodies anti-Ro/SSA and anti-La/SSB
Study: 11738121
Drug: Antiretroviral treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral treatments
Study: 2456174
Drug: Iloprost at
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost at a dose of 2 ng/kg/min for 6 hours daily for 6 days
Study: 2456174
Drug: Iloprost at
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost at a dose of 1 ng/kg/min for 6 hours daily for 6 days
Study: 24973862
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg omega‐3 fatty acid supplements (n = 28)
Study: 20868638
Drug: EGb-761, 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb-761, 240 mg/d
Study: 19246729
Drug: nelfinavir 1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: nelfinavir 1250 mg every 12 hours on days 1-4
Study: 19246729
Drug: nelfinavir 1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: nelfinavir 1250 mg every 12 hours on days 1-3 plus 3125 mg on day 4
Study: 19246729
Drug: moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: moxifloxacin 400 mg every 24 hours on days 1-4
Study: 15749042
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg daily for 3 days)
Study: 16618915
Drug: Telithromycin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telithromycin (800 mg daily for 5 days)
Study: 15585764
Drug: Cystine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cystine intake of 5 mg.kg(‐1).d(‐1)
Study: 15585764
Drug: Cystine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cystine intake of 12 mg.kg(‐1).d(‐1)
Study: 15585764
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg cystine intake (previously estimated)
Study: 9480466
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose methotrexate (7.5-15 mg weekly)
Study: 8492409
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (intermediate dose cytosine arabinoside (Ara‐C), cyclophosphamide (CPM) plus 6MP)
Study: 8492409
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (high-dose Ara‐C plus CPM)
Study: 31818531
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of refined cold-pressed flaxseed oil providing 4.7 g ALA (n = 29)
Study: 31818531
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of high-oleic sunflower oil (control) (n = 30)
Study: 29019418
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care plus daily motivational interviewing-based text messages
Study: 28961714
Drug: Intravenous posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous posaconazole 300 mg twice daily on day 1, followed by 300 mg once daily for 4-28 days, then oral posaconazole 400 mg twice daily or 200 mg three times daily for 28 days.
Study: 26290323
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment with concentrated blood and bone marrow aspirate (cB + cBMA)
Study: 26290323
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment without cB + cBMA (sham treatment)
Study: 23406601
Drug: Intranasal fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal fluticasone furoate (FF) and intraocular placebo (PL)
Study: 23406601
Drug: Intranasal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal placebo (PL) and intraocular olopatadine (OLO)
Study: 23406601
Drug: Intranasal fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal fluticasone furoate (FF) and intraocular olopatadine (OLO)
Study: 23406601
Drug: Intranasal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal placebo (PL) and intraocular placebo (PL)
Study: 23406601
Drug: Intranasal fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal fluticasone furoate (FF)
Study: 18001177
Drug: Antithyroid drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithyroid drugs (ATDs) therapy in Graves' disease
Study: 18001177
Drug: Antithyroid drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithyroid drugs (ATDs) therapy in painless thyroiditis
Study: 15256294
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (30-min massages three times per week for 5 weeks)
Study: 9416722
Drug: Rocuronium 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 1.2 mg/kg (three times the ED95)
Study: 9416722
Drug: Succinylcholine 2
Normalized name: succinylcholine 20 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 2 mg/kg
Study: 8236504
Drug: RT plus
Normalized name: Recort Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT plus NTX (100 mg every other day)
Study: 26272704
Drug: Single-visit treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-visit treatment
Study: 26272704
Drug: Multiple-visit treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-visit treatment
Study: 21290248
Drug: Racemic cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic cyclophosphamide (CYC) 900 or 1,000 mg/m²
Study: 19717250
Drug: Contingency management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingency management with clinic-delivered, abstinence-based incentive program and weekly behavioral parent training sessions
Study: 19717250
Drug: Attendance-based incentive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attendance-based incentive program and weekly psychoeducational parent sessions (Control)
Study: 19717250
Drug: Both conditions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both conditions (MET/CBT and drug-testing program)
Study: 17704421
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus surgery (preoperative cisplatin plus fluorouracil)
Study: 17704421
Drug: Objective tumor
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Objective tumor regression after preoperative chemotherapy
Study: 2442415
Drug: Sodium pentosanpolysulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium pentosanpolysulfate (200 mg twice daily)
Study: 31937532
Drug: Morning warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning warfarin ingestion
Study: 31937532
Drug: Evening warfarin
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening warfarin ingestion
Study: 31037289
Drug: Aflibercept (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept (2.0 mg intravitreous injection, n = 226)
Study: 23575197
Drug: Telaprevir (TVR)
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telaprevir (TVR) treatment
Study: 19803620
Drug: Family intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Family intervention to improve medication adherence and reduce relapse
Study: 17103307
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g L-Arg
Study: 17103307
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g L-Arg
Study: 14523338
Drug: 0.05% GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% GTN ointment
Study: 14523338
Drug: 0.1% GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% GTN ointment
Study: 1559321
Drug: Disopyramide (D.RET.)
DrugBank: Disopyramide (DB00280)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disopyramide (D.RET.) 250 mg twice daily
Study: 1559321
Drug: Amiodarone 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone 1200 mg daily for 10 days, then 200 mg daily
Study: 4014620
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg controlled-release oral morphine
Study: 4014620
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg controlled-release oral morphine
Study: 4014620
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg intramuscular morphine
Study: 29739782
Drug: Digital self‐management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital self‐management intervention for blood pressure self‐monitoring and medication change
Study: 12032741
Drug: Herbal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal treatment (90 mg ephedrine alkaloids and 192 mg caffeine per day)
Study: 1467659
Drug: Local intravaginal
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local intravaginal application of metronidazole (500 mg)
Study: 1467659
Drug: Single-shot prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-shot prophylaxis with cefuroxime (1,500 mg intravenously)
Study: 6507770
Drug: Bupivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine with initial peridural injection of 100 μg fentanyl
Study: 30122200
Drug: Test product
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product containing hydrolyzed fish collagen, vitamins, antioxidants, and other active ingredients, taken daily for 90 days.
Study: 11236211
Drug: Combination topical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination topical gel (5% benzoyl peroxide and 1% clindamycin)
Study: 7657446
Drug: 1% clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% clindamycin gel
Study: 9428832
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg daily
Study: 9428832
Drug: Metformin 1000
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1000 mg daily
Study: 9428832
Drug: Metformin 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1500 mg daily
Study: 29659896
Drug: Metformin 2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 2000 mg daily
Study: 9428832
Drug: Metformin 2500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 2500 mg daily
Study: 3303439
Drug: Azathioprine and
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine and low-dose prednisolone (AP)
Study: 2526721
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA), 150 mg/day
Study: 4602899
Drug: To‐336 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: To‐336 vaccine
Study: 4602899
Drug: HPV77. DE‐5
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV77. DE‐5 vaccine
Study: 4602899
Drug: RA27/3 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RA27/3 vaccine
Study: 619075
Drug: Cendehill vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cendehill vaccine
Study: 31400515
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of CBT and modafinil for 12 weeks
Study: 31400515
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of CBT and modafinil
Study: 28203020
Drug: CFNB combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFNB combined with PLIA (20 mL ropivacaine 5 g/L)
Study: 16763334
Drug: IFN‐a2a (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐a2a (9 MU three times a week) and lamivudine (100 mg daily) for 12 months (Group 1)
Study: 17040264
Drug: Tacrolimus ointment
Normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus ointment 0.1%
Study: 9024746
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogen (0.625 mg/day of Premarin)
Study: 7744191
Drug: Bambuterol 10
Normalized name: bambuterol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bambuterol 10 mg
Study: 7744191
Drug: Bambuterol 20
Normalized name: bambuterol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bambuterol 20 mg
Study: 8299660
Drug: Terbutaline 7.5
Normalized name: terbutaline 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 7.5 mg
Study: 8299660
Drug: Bambuterol 10
Normalized name: bambuterol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bambuterol 10 mg vs Terbutaline 7.5 mg
Study: 8299660
Drug: Bambuterol 10
Normalized name: bambuterol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bambuterol 10 mg vs Bambuterol 20 mg
Study: 8299660
Drug: Bambuterol 20
Normalized name: bambuterol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bambuterol 20 mg vs Terbutaline high dose
Study: 3571318
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment of ligamentous injuries
Study: 3571318
Drug: Non-surgical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical treatment of ligamentous injuries
Study: 26433763
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) in routine care
Study: 26433763
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) in RCTs
Study: 25551813
Drug: Combined sciatic-femoral
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined sciatic-femoral nerve block with levobupivacaine 0.5% (40 ml)
Study: 25551813
Drug: Spinal anaesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthesia with 7.5 mg levobupivacaine 0.5%
Study: 22286203
Drug: aripiprazole 2
Normalized name: aripiprazole 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: aripiprazole 2 mg/day
Study: 16330624
Drug: Systematic detection
Normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic detection and multidisciplinary treatment of depression (consultation and treatment by a psychiatrist, follow-up by a research nurse and family physician)
Study: 12698500
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg bid of theophylline (Unilong)
Study: 12698500
Drug: 375 mg
Normalized name: niacin 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg bid of theophylline (Unilong)
Study: 10648261
Drug: 1 L
Normalized name: BLUE 1 LAKE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L unfiltered cafetière (French press) coffee daily for 2 weeks
Study: 3321397
Drug: Low-dose antacid
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose antacid treatment with additional ranitidine
Study: 3321397
Drug: Low-dose antacid
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose antacid treatment without ranitidine
Study: 30591198
Drug: Topical diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diltiazem applied three times a day
Study: 28931618
Drug: Oral anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulants (warfarin)
Study: 22554354
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg day(‐1) for 4 days)
Study: 22554354
Drug: Itraconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (200 mg day(‐1) for 6 days)